Last reviewed · How we verify
H5N1 VLP Vaccine
H5N1 VLP Vaccine is a Biologic drug developed by Novavax. It is currently in Phase 1 development.
At a glance
| Generic name | H5N1 VLP Vaccine |
|---|---|
| Sponsor | Novavax |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers (PHASE1)
- Safety, Reactogenicity and Immunogenicity of an H5N1 VLP (PHASE1, PHASE2)
- Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H5N1 VLP Vaccine CI brief — competitive landscape report
- H5N1 VLP Vaccine updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about H5N1 VLP Vaccine
What is H5N1 VLP Vaccine?
H5N1 VLP Vaccine is a Biologic drug developed by Novavax.
Who makes H5N1 VLP Vaccine?
H5N1 VLP Vaccine is developed by Novavax (see full Novavax pipeline at /company/novavax).
What development phase is H5N1 VLP Vaccine in?
H5N1 VLP Vaccine is in Phase 1.
Related
- Manufacturer: Novavax — full pipeline
- Compare: H5N1 VLP Vaccine vs similar drugs
- Pricing: H5N1 VLP Vaccine cost, discount & access